

Mouse FCRLA Alexa Fluor® 488-conjugated Antibody

Antigen Affinity-purified Polyclonal Sheep IgG Catalog Number: AF7905G

100 µg

DESCRIPTION	
Species Reactivity	Mouse
Specificity	Detects mouse FCRLA in direct ELISAs and Western blots. In direct ELISA, less than 5% cross-reactivity with recombinant human FCRLA is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	E. coli-derived recombinant mouse FCRLA Lys221-Lys352 (Ile321Met) Accession # Q920A9
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

China | info.cn@bio-techne.com TEL: 400.821.3475

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

FCRLA (Fc Receptor-Like A; also known as FcRX and Fc receptor Homolog Expressed in B cells) is a 44 kDa intracellular member of the FcγRI class, FcR family, Immunoglobulin Superfamily of molecules. It is associated with B lineage cells, and has been identified in virtually all splenic B cells, peritoneal B1b and B2 B cells, and immature through mature bone marrow B cells. Not all cells show equal expression patterns. In the spleen, weak FCRLA expression occurs in naïve follicular and marginal zone B cells, and increases with activation state. FcRLA is suggested to act as an ER chaperone during antibody maturation, and is known to bind to IgM, IgA, and IgG prior to their secretion. Mouse FCRLA is synthesized as a 34 kDa, 322 amino acid (aa) precursor that contains a 30 aa signal sequence, two C2-type Ig-like domains (aa 80-169 and 182-26), and a C-terminal poly-Proline region (aa 289-294). Although there is no traditional ER retention signal, a viable substitute is assumed to exist at the N-terminus of the mature molecule. FCRLA is believed to exist naturally as a monomer; however, disulfide-linkage can occur during experimental manipulation. While four potential isoform variants are reported, it is unclear if any are actually expressed. One shows an Ala insertion after Ala28, a second shows an Alalle substitution for aa 20-22, a third contains that previous Alalle substitution coupled to a deletion of aa 90-115, while a fourth utilizes an alternative start site at Met62. Over aa 221-352, mouse FCRLA shares 68% and 55% aa sequence identity with rat and human FCRLA, respectively.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 9/16/2025 Page 1 of 1

Global | bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL: 1.612.379.2956